Lopinavir/Ritonavir plus Lamivudine/Zidovudine — Competitive Intelligence Brief

Lopinavir/Ritonavir plus Lamivudine/Zidovudine (Lopinavir/Ritonavir plus Lamivudine/Zidovudine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors). Area: Infectious

phase 3 Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) HIV protease, HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Lopinavir/Ritonavir plus Lamivudine/Zidovudine (Lopinavir/Ritonavir plus Lamivudine/Zidovudine) — University of Cologne. This combination inhibits HIV protease and reverse transcriptase to suppress viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lopinavir/Ritonavir plus Lamivudine/Zidovudine TARGET	Lopinavir/Ritonavir plus Lamivudine/Zidovudine	University of Cologne	phase 3	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Atazanavir, ritonavir, lamivudine	Atazanavir, ritonavir, lamivudine	Catholic University of the Sacred Heart	marketed	Antiretroviral combination (protease inhibitor + NRTI)	HIV protease, HIV reverse transcriptase
Ritonavir boosted Atazanavir + 2 NRTIs	Ritonavir boosted Atazanavir + 2 NRTIs	Fundacion SEIMC-GESIDA	marketed	Protease inhibitor combination antiretroviral therapy	HIV protease, HIV reverse transcriptase
Lopinavir/ritonavir + zidovudine + lamivudine	Lopinavir/ritonavir + zidovudine + lamivudine	Amsterdam UMC, location VUmc	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Atazanavir + Ritonavir + 2 NRTIs	Atazanavir + Ritonavir + 2 NRTIs	Bristol-Myers Squibb	marketed	Antiretroviral combination therapy (protease inhibitor + pharmacokinetic booster + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase, cytochrome P450 (CYP3A4)
lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine	lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine	University of British Columbia	marketed	Antiretroviral combination therapy (protease inhibitor + non-nucleoside reverse transcriptase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Darunavir, Ritonavir and Rilpivirine	Darunavir, Ritonavir and Rilpivirine	St Stephens Aids Trust	marketed	Antiretroviral combination (protease inhibitor + NNRTI)	HIV protease, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) class)

1. Bristol-Myers Squibb · 3 drugs in this class
2. Juan A. Arnaiz · 2 drugs in this class
3. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
4. The HIV Netherlands Australia Thailand Research Collaboration · 1 drug in this class
5. University of Cologne · 1 drug in this class
6. Amsterdam UMC, location VUmc · 1 drug in this class
7. ViiV Healthcare · 1 drug in this class
8. Drugs for Neglected Diseases · 1 drug in this class